The Public M&A and Life Sciences teams advised longtime Goodwin client MyoKardia, Inc. on the successful completion of its acquisition by Bristol Myers Squibb in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. Bristol Myers Squibb’s previously announced tender offer for all outstanding shares of common stock of MyoKardia for $225.00 per share expired at the end of the day on November 16, 2020.
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Through this transaction, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease with high morbidity and patient impact.
The Goodwin team was led by Stuart Cable, Lisa Haddad, Mitchell Bloom, Mike Patrone and Maggie Wong with invaluable assistance from Kirby Lewis, Sarah Bock, Robert Crawford, Stephanie Philbin, Daniel Karelitz, Michael Jones, Jennifer Fay, Natalie Martirossian, Jackie Klosek, Grace Wirth, Cecelia Lockner, William Stanton, Andre Amorim, Nicole Spiteri and Sophie Duffy.
For additional details on the closing, please read the press release.